Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milrinone for prevention of delayed cerebral ischemia after severe subarachnoid hemorrhage
2019-000509-58Phase 3Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and delayed cerebral ischemia (DCI) comparing Milrinone with Placebo (2 arms). Primary endpoint: Volume of delayed cerebral ischemia lesions on MRI at 1 month. Started Aug 2019; status: active.
02
Drugs
milrinone
03
Conditions
subarachnoid hemorrhage (SAH)delayed cerebral ischemia (DCI)
Beyond the preview
Go deeper on 2019-000509-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000509-58.